UBS remains bullish on Eli Lilly’s future thanks to surging demand for its obesity and diabetes treatments. UBS predicts Zepbound sales could exceed market expectations by roughly 15%. Meanwhile, ...

A company expected to fare well during this time is Eli Lilly, with revenue forecast to improve by 165% in 2030. This will largely be driven by the company’s glucagon like peptide-1 receptor agonist ...

According to UBS, the company’s next major driver is the SURPASS cardiovascular outcomes trial. The bank added that Eli Lilly ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

Eli Lilly stock currently trades below its 50-week average, offering a strong entry point despite continued dominance in ...

These popular medications are now at the center of a major weight loss drug lawsuit. Find out which drugs and involved and ...

These can include weight loss, loss of appetite, yellowing of the skin, vomiting or nausea, and the symptoms of diabetes ...

A cyberattack on Synnovis has been linked to a patient's death at King's College Hospital, marking a serious hacking ...

These six stocks span numerous sectors, providing investors with opportunities in both growth and dividend yield.

GLP-1 drugs, which have seen widespread success, have been linked to a number of cases of pancreatitis in the UK, which have ...

Health news includes a cyberattack affecting patient care in London, Walgreens' financial success amid strategic changes, ...

Altimmune’s pemvidutide failed to significantly improve fibrosis in MASH patients in a Phase IIb study. The biotech crashed ...